✦ LIBER ✦

A phase I study of the oral vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 on a twice daily schedule in patients with advanced cancer

Book ID: 117659588
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 143 KB
Volume: 38
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(02)80896-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PTK787/ZK 222584, a small molecule tyros

PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia

✍ Francis J. Giles; Alan F. List; Michael Carroll; Jorge E. Cortes; Joyce Valickas 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 151 KB

35 POSTER A Phase I trial of a combinati

35 POSTER A Phase I trial of a combination of the mToR Inhibitor Everolimus (RAD001) and two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor Vatalanib (PTK787/ZK222584) in patients (pts) with advanced solid tumors

✍ G. Dy; G. Croghan; A. Furth; J. Reid; L. Hanson; M. Roos; A. Tan; A. Adjei 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 134 KB

Biomarkers for assessment of pharmacolog

Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases

✍ Lucy Lee; Sunil Sharma; Bruno Morgan; Peter Allegrini; Christian Schnell; Josef 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 427 KB

Defining the biologically active dose fo

Defining the biologically active dose for PTK787/ZK222584 (ptk/zk), a vascular endothelial growth factor (VEGF) receptor inhibitor, based on the assessment of two biomarkers [dynamic contrast enhanced magnetic resonance imaging (DCE-MRI), plasma VEGF] in two phase I studies

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 141 KB

Phase II Study of Cediranib, an Oral Pan

Phase II Study of Cediranib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

✍ Batchelor, T. T.; Duda, D. G.; di Tomaso, E.; Ancukiewicz, M.; Plotkin, S. R.; G 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 107 KB

Phase I and pharmacokinetic study of TSU

Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors

✍ Yutaka Ueda; Tatsu Shimoyama; Haruyasu Murakami; Noboru Yamamoto; Yasuhide Yamad 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 472 KB